Andrew Kin is a Hematology physician affiliated with The Barbara Ann Karmanos Cancer Institute. OpenAlex indexes 72 publications with 241 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4100 John R St
Detroit, MI 482012013
Telephone
800-527-6266Registry record last updated 9 Apr 2019.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Celgene CorporationProgram year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.8%Thalidomide Analog57.8%Revlimid100%Part D≥22 patientsDermatology
19.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.3%Acyclovir100%Part D≥11 patientsRespiratory
12.8%Opioid Agonist12.8%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Journal of Clinical Oncology
2026 - A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis
Bone Marrow Transplantation
2025 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C)
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Schiffer, MD
The Barbara Ann Karmanos Cancer Institute
Joseph Uberti, MD, PhD
The Barbara Ann Karmanos Cancer Institute
Jose Larios, MD
The Barbara Ann Karmanos Cancer Institute
Borys Hrinczenko, MD
The Barbara Ann Karmanos Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”